Unknown

Dataset Information

Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs.


ABSTRACT:

Background

Itraconazole is commonly used to treat systemic fungal infections in dogs, but problems exist with absorption and cost.

Objective

To determine oral bioequivalence of generic and compounded itraconazole compared to original innovator (brand name) itraconazole in healthy dogs.

Animals

Nine healthy, adult research Beagle dogs.

Methods

A randomized, 3-way, 3-period, crossover design with an 8-day washout period. After a 12-hour fast, each dog received 100 mg (average: 10.5 mg/kg) of either innovator itraconazole, an approved human generic capsule, or compounded itraconazole (compounded using a commercially available compounding vehicle) with a small meal. Plasma was collected at predetermined intervals for high pressure liquid chromatography analysis. Co

SUBMITTER: Mawby DI 

PROVIDER: S-EPMC4895533 | biostudies-literature | 2014 Jan-Feb

REPOSITORIES: biostudies-literature